Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 3Pancreatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Hypoxia 2Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 23Nivolumab 20atezolizumab 10Specimen Handling 8Ipilimumab 8Cyclophosphamide 8cabozantinib 6Magnetic Resonance Spectroscopy 6fludarabine 5Sorafenib 5sargramostim 4Trastuzumab 4Sunitinib 4Bevacizumab 4lenvatinib 3enzalutamide 3durvalumab 3avelumab 3X-Rays 3Paclitaxel 3Fluorodeoxyglucose F18 3Docetaxel 3Albumin-Bound Paclitaxel 3ulixertinib 2spartalizumab 2relatlimab 2regorafenib 2palbociclib 2epacadostat 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × TH 302 × Genitourinary × Clear all
NCT01497444 2020-02-06

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

Alliance for Clinical Trials in Oncology

Phase 1 Completed
24 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡